Trial intelligence / Profile preview

Tigecycline vs Ceftriaxone + Metronidazole in cIAI

NCT00195351Phase 4Completed

Sponsor
Pfizer
Start
Sep 2005
Primary completion
Feb 2008
Modality
Orthosteric Ligands
Countries
6
01

Overview

Phase 4, randomised, open-label trial of tigecycline in Intra-abdominal infection (IAI) (2 arms), sponsored by Pfizer. Primary endpoint: Clinical Response of Cure at Test-of-Cure (TOC) Visit. Started Sep 2005; status: completed.

02

Drugs

tigecycline
03

Conditions

Intra-abdominal infection (IAI)

Beyond the preview

Go deeper on NCT00195351.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00195351.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call